SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 1,799 Shares

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 1,799 shares of SiBone stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $12.95, for a total value of $23,297.05. Following the completion of the sale, the senior vice president directly owned 284,175 shares in the company, valued at approximately $3,680,066.25. The trade was a 0.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

SiBone Price Performance

Shares of NASDAQ SIBN remained flat at $13.12 during midday trading on Friday. The stock had a trading volume of 673,231 shares, compared to its average volume of 599,931. The company has a quick ratio of 7.21, a current ratio of 8.55 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $579.51 million, a PE ratio of -29.82 and a beta of 0.77. SiBone has a 52-week low of $12.15 and a 52-week high of $21.89. The stock has a 50 day moving average of $14.69 and a 200 day moving average of $16.39.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.09. The company had revenue of $56.35 million for the quarter, compared to analysts’ expectations of $56.26 million. SiBone had a negative net margin of 9.41% and a negative return on equity of 11.01%. As a group, equities analysts forecast that SiBone will post -0.78 EPS for the current year.

Institutional Investors Weigh In On SiBone

Several hedge funds and other institutional investors have recently made changes to their positions in the company. First Light Asset Management LLC lifted its holdings in shares of SiBone by 162.4% in the 4th quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock worth $99,249,000 after acquiring an additional 3,115,001 shares during the last quarter. American Century Companies Inc. grew its holdings in SiBone by 22.5% during the 3rd quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock valued at $41,777,000 after purchasing an additional 521,683 shares during the last quarter. Vanguard Group Inc. raised its position in SiBone by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company’s stock worth $49,331,000 after purchasing an additional 11,566 shares during the period. Nuveen LLC lifted its stake in SiBone by 5.1% in the fourth quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock worth $28,041,000 after purchasing an additional 69,229 shares during the last quarter. Finally, Impax Asset Management Group plc lifted its stake in SiBone by 17.1% in the fourth quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company’s stock worth $23,664,000 after purchasing an additional 175,000 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SIBN. TD Cowen upped their target price on shares of SiBone from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Truist Financial reiterated a “buy” rating and issued a $24.00 price target (up from $23.00) on shares of SiBone in a research report on Tuesday, February 24th. Needham & Company LLC boosted their price objective on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Canaccord Genuity Group raised their price objective on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Wall Street Zen upgraded SiBone from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.67.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.